VEGFA and hepatocellular carcinoma: Following the practice-changing phase III IMbrave150 trial, the combination of atezolizumab (anti-PD-1 mAb) and bevacizumab (anti-VEGF mAb) was approved as a first-line treatment in advanced HCC, replacing sorafenib, thanks to an impressive mOS of 19.2 months (vs. 13.4 months for sorafenib, HR = 0.66 p < 0.001) [25,26,27].